Wellmark coverage for Wegovy (Heart Disease Risk

Employer / Commercial Insurance

Depends on your plan's benefit

Covered only for select plans with specific benefit language allowing coverage of drugs for weight loss management or weight-related comorbidities; drugs for weight loss management are a standard exclusion for most benefit plans

What you need to qualify

Age 18 and older
BMI of 27 or higher
6 months of a documented diet and exercise program
Established cardiovascular disease (MI, stroke, and PAD)
On guideline-directed medical therapy (antiplatelet, lipid-lowering, and antihypertensive)
Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

CV Risk Reduction - Continuation/Already on therapy

All of:

Patient is 18 years of age or older
Patient has completed at least 3 months of therapy with Wegovy at a stable maintenance dose
Patient lost at least 5% of baseline body weight OR has continued to maintain their initial 5% weight loss (documentation required)
Patient is currently on and will continue to be on a weight loss regimen of reduced calorie diet, increased physical activity, and behavioral modifications
Patient will NOT be using the requested agent in combination with another targeted weight loss agent
Patient does not have a diagnosis of diabetes mellitus or pancreatitis within 180 days prior to the request

CV Risk Reduction - New to therapy

All of:

Patient is 18 years of age or older
Patient has participated in a comprehensive weight management program encouraging behavioral modification, reduced calorie diet and increased physical activity with continuing follow-up for at least 6 months prior to drug therapy
Patient has a baseline BMI >= 27 kg/m2
Patient has established cardiovascular disease defined by previous myocardial infarction, previous stroke, or symptomatic peripheral arterial disease (intermittent claudication with ankle-brachial index <0.85 at rest, peripheral arterial revascularization procedure, or amputation due to atherosclerotic cardiovascular disease) — documentation required
Patient is receiving and will continue standard of care treatment of cardiovascular disease including a drug from each of: antiplatelet (e.g., aspirin, P2Y12 receptor blocker), lipid-lowering (e.g., statin, ezetimibe, PCSK9 inhibitors), antihypertensive (e.g., beta-blocker, ACE inhibitors or ARBs) unless inadequate response, intolerance, documented contraindication, or medically justifiable reason to preclude use of all medications in any/all classes — documentation required
Patient does not have a diagnosis of diabetes mellitus or pancreatitis within 180 days prior to the request
Patient is currently on and will continue to be on a weight loss regimen of reduced calorie diet, increased physical activity, and behavioral modifications
Patient will NOT be using the requested agent in combination with another targeted weight loss agent

Documentation to bring

Chart notes or medical record documentation of Body Mass Index (BMI)
Chart notes, medical record documentation, or claims history supporting established cardiovascular disease (i.e., previous myocardial infarction, previous stroke, or symptomatic peripheral arterial disease)
Documentation of current standard of care treatment of cardiovascular disease including antiplatelet, lipid-lowering, and antihypertensive therapy (or clinical reason any class is not appropriate)
Documentation confirming no diagnosis of diabetes mellitus or pancreatitis within 180 days prior to the request
Documentation of at least 5% baseline body weight loss or maintained 5% weight loss (for continuation)

Quantity limits

All strengths — 4 pens

Approval and renewal

Initial approval: 6 months
Renewal: every 12 months
To renew, the plan looks for at least 5% weight loss from the starting weight, Lost at least 5% of baseline body weight OR maintained initial 5% weight loss after at least 3 months at stable maintenance dose, and at least 12 weeks on therapy before the first renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

Diagnosis of diabetes mellitus within 180 days prior to the request
Diagnosis of pancreatitis within 180 days prior to the request
Combination use with another targeted weight loss agent
Plans without specific benefit language allowing weight loss drug coverage

Policy note: GDMT classes required are antiplatelet (e.g., aspirin, P2Y12 receptor blocker), lipid-lowering (e.g., statin, ezetimibe, PCSK9 inhibitors), and antihypertensive (e.g., beta-blocker, ACE inhibitors, or ARBs). Exceptions allowed for inadequate response, intolerance, documented contraindication, or medically justifiable reason. The 180-day diabetes/pancreatitis exclusion window applies to the initial approval pathway; the continuation pathway also requires 5% weight loss maintained at 3 months on stable maintenance dose. Covers Wegovy injection, Wegovy HD injection, and Wegovy tablet. Approval duration stated as 6 months for initial for 'weight loss and cardiovascular risk reduction' combined.

Policy effective May 19, 2026 · verified June 3, 2026 · source: Drugs-for-weight-loss-management.pdf

Wellmark coverage for Wegovy (Heart Disease Risk Reduction)